AlloNK and rituximab for relapsing rheumatologic diseases
Part of Bones, joints & muscles, Brain & nervous system, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial tests a new natural killer (NK) cell therapy called AlloNK given with rituximab for people with certain autoimmune diseases (rheumatoid arthritis, Sjögren's disease, inflammatory myopathies, or systemic sclerosis) that have not responded well to standard treatments. The goal is to see if this combination can better control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these four conditions: rheumatoid arthritis, Sjögren's disease, inflammatory myopathy, or systemic sclerosis.
- Your disease must be active and not well controlled by standard treatments.
- You need to have certain lab tests or physical findings that confirm active disease (like swollen joints, specific antibodies, or skin score).
- You need to have tried at least one biologic or immunosuppressive medicine for at least 3 months and it didn't work or you couldn't tolerate it.
- Your diagnosis must meet established medical criteria for your condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy using modified natural killer cells (CAR-NK) that target a protein called CD19 and produce helpful signals (IL-10 and IL-15). It is for people with certain autoimmune diseases that have not improved with standard treatments or have come back after getting better.
This study tests whether combining immune cells (NK cells) with rituximab can help people with hard-to-treat lupus or lupus-related kidney disease. It is for patients whose lupus is still active despite standard treatments.
This trial tests a new one-time cell therapy (ALLO-329) made from donor cells to target and calm overactive immune cells in people with lupus, myositis, or scleroderma that hasn't improved with usual medications. It aims to see if this treatment is safe and can help reduce disease activity.
This trial tests an investigational cell therapy called NKX019 for people with certain autoimmune diseases like scleroderma, myositis, vasculitis, or rheumatoid arthritis. It aims to see if NKX019 can help control the disease when standard treatments have not worked well enough.
This trial tests combining two drugs (rituximab and tafasitamab) with donor natural killer (NK) cells to treat B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatments. The goal is to see if this combination can help the immune system fight the cancer more effectively.
This study tests an investigational injection called RN1201 for people whose autoimmune disease (like lupus, myasthenia gravis, or immune thrombocytopenia) has not responded to standard therapies. The goal is to see if it can better control the disease.
Hear when a new Idiopathic Inflammatory Myopathies (IIMs) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.